Textbook of Personalized Medicine - Second Edition [2015]

406 Personalized Management of Malaria Worldwide there are ~500 million new cases of malaria per year. Malaria is caused by a pr ...

407 Through rapid genetic adaptation and natural selection, the P. falciparum parasite, the cause of the most serious form of ma ...

408 Kotsaki A, Giamarellos-Bourboulis EJ. Molecular diagnosis of sepsis. Expert Opin Med Diagn. 2012;6:209–19. Laabei M, Recker ...

K.K. Jain, Textbook of Personalized Medicine, DOI 10.1007/978-1-4939-2553-7_12,^409 © Springer Science+Business Media New York 2 ...

410 Applications of Neurogenomics in Neurological Disorders Many neurological conditions are caused by immensely heterogeneous g ...

411 which are responsible for the underlying disorder. The high number of rare, heteroge- neous mutations present in all humans ...

412 Impact of Neurogenomics on the Development of Personalized Neurology Genomics is improving our understanding of neurologic d ...

413 Targeting the complete mitochondrial exome provides a greater potential to identify rare variants that disrupt normal mitoch ...

414 Regeneration and Degeneration of the Nervous System Neuroproteomic tech- nologies have been designed to uncover the mechanis ...

415 are found in Creutzfeldt-Jacob disease than in other diseases. However, this test does not replace brain biopsy for defi nit ...

416 Small infarcts and transient ischemic attacks elevate only neuron-specifi c enolase. Peak levels of both neuron-specifi c en ...

417 Neurometabolomics Role of metabolomics in personalized medicine was described in Chap. 7. Neurometabolomics is the study of ...

418 Ex vivo gene therapy involves the genetic modifi cation of the patient’s cells in vitro, mostly by use of viral vectors, pri ...

419 risk of developing AD. The ApoE e4 allele, a risk factor rather than a disease gene, has a positive predictive value of 94–9 ...

420 Genomic Basis of Personalized Approach to Alzheimer Disease Alzheimer’s disease (AD) is a polygenic disorder and several gen ...

421 late-onset AD, suggesting a potentially new way to treat or even prevent the disease (Dreses- Werringloer et al. 2008 ). Gen ...

422 of levodopa dose. Results of clinical studies, however, indicate that COMT genotype seems to be a minor factor in judging th ...

423 Role of Pharmacogenetics in Personalizing Therapy of PD Cytochrome P450 CYP2D6 enzyme, which metabolizes many drugs, is also ...

424 Personalized Cell Therapy for PD Various types of cell therapy have been used for PD but none of these has so far proven ent ...

425 Genetic Testing for HD Predictive testing for HD had been available for some time before the HD gene was cloned. In these pr ...